Results for tag: "Tremelimumab"

Tremelimumab is a monoclonal antibody drug used to treat certain types of lung cancer. It works by targeting a protein called CTLA-4, which is found on the surface of certain immune cells. By blocking CTLA-4, tremelimumab helps the body's immune system to recognize and attack cancer cells. It is approved for use in combination with other drugs to treat advanced non-small cell lung cancer (NSCLC) in adults who have not responded to other treatments. Tremelimumab is administered intravenously and is usually given in combination with other drugs. Common side effects include fatigue, nausea, and diarrhea. More serious side effects can include inflammation of the lungs, liver, or pancreas. Tremelimumab is a relatively new drug and is not yet widely available. It is currently being studied in clinical trials for other types of cancer, including melanoma and bladder cancer. Some companies in the tremelimumab market include Bristol-Myers Squibb, Merck, and AstraZeneca. Show Less Read more